Alexion wins EMA nods for not one but two drugs

Rare-disease specialist Alexion Pharmaceuticals ($ALXN) won a double header from the EMA today when the agency recommended approval of two of its drugs, including Kanuma, the enzyme replacement med it picked up in its $8.4 billion buyout of Synageva. It was approved to treat all ages for lethal cases of early onset lysosomal acid lipase deficiency. Alexion also won approval for Strensiq for long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia to treat the bone manifestations of the disease, the company said. Approvals from the EMA generally come several months after a recommendation. Story | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.